Dose-related reductions in prefrontal recruitment during cognitive reappraisal following oral delta-9-tetrahydrocannabinol in posttraumatic stress disorder.

In 30 seconds

This randomized controlled trial examined the effects of oral delta-9-tetrahydrocannabinol (THC) on prefrontal activation during cognitive reappraisal in adults with posttraumatic stress disorder (PTSD). Participants received either placebo, 5 mg, or 10 mg of THC. Results showed that both THC doses led to reduced prefrontal activation during reappraisal of negative images compared to placebo, with the 10 mg dose showing broader and stronger effects.

Key findings

• Both THC doses reduced prefrontal activation during cognitive reappraisal compared to placebo.
• The 10 mg THC dose resulted in broader and stronger reductions in activation.
• In-scanner negative affect ratings did not differ by THC dose.
• Post-scan ratings confirmed expected stimulus effects without reliable dose effects.

Why it matters

Understanding the impact of THC on neural mechanisms in PTSD can inform treatment approaches for emotion regulation. The findings suggest a potential neural-subjective dissociation that may influence therapeutic strategies.